Navigation Links
Spherix Holds Annual Shareholders Meeting
Date:5/14/2008

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- At their 2008 Annual Meeting, shareholders of Spherix Incorporated (Nasdaq: SPEX) elected the following members to the Board of Directors:

-- Douglas T. Brown, Senior VP and Manager of Corporate Banking Government

Contracting, PNC Bank

-- A. Paul Cox, Jr., Principal, Asset Protection Company

-- Claire L. Kruger, Chief Executive Officer and Chief Operating Officer,

Spherix

-- Gilbert V. Levin, Ph.D., Director of Science and Technology, Spherix

-- Robert A. Lodder, Jr., President, Spherix; and Professor, College of

Pharmacy, University of Kentucky

-- Aris Melissaratos, Senior Advisor to the President of Johns Hopkins

University

-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods

International

In addition, Grant Thornton LLP was ratified as the Company's independent accountants for the year 2008.

Claire Kruger told the shareholders that Spherix management is focused and will continue to focus on the path forward necessary to bring Naturlose to market as a drug to treat Type 2 diabetes. To this end, three crucial activities are being undertaken in parallel:

1) Optimizing the efficiency and effectiveness of the clinical trial

program;

2) Evaluating the diabetes drug market potential to determine opportunity

and provide a clear understanding of our potential value;

3) Assuring supplies of tagatose, both the cGMP batches needed for the NDA

as well as a supplier to hold the Drug Master File once FDA approval

has been achieved.

At a Board of Directors meeting later the same day, the following slate of Corporate Officers was elected:

-- Paul Cox, Chairman of the Board

-- Claire Kruger, Chief Executive Officer and Chief Operating Officer

-- Robert Lodder, President

-- Robert Clayton, Interim Chief Financial Officer and Treasurer

-- Katherine Brailer, Corporate Secretary and Director of Administrative

Services

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is http://www.spherix.com.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Hires Key Employees
2. Spherix Reports 2007 Financial Results
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. Sinovac Biotech Holds Annual General Meeting
6. New Robotic Imaging Technology Holds Promise of Improved Cancer Care
7. Vion Pharmaceuticals Holds Special Meeting of Stockholders
8. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
9. Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing
10. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
11. CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
Breaking Biology News(10 mins):